Alnylam Pharmaceuticals Sustainability Profile
Alnylam Pharmaceuticals, a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has made significant strides in the development of innovative treatments for rare genetic diseases, positioning itself as a leader in the industry. With a strong operational presence in key regions, including Europe and Asia, Alnylam focuses on delivering transformative medicines that target the underlying causes of diseases. Its core products, such as ONPATTRO and GIVLAARI, are distinguished by their unique mechanism of action, offering patients new hope where traditional therapies have fallen short. Recognised for its commitment to scientific excellence, Alnylam has achieved numerous milestones, including the first-ever approval of an RNAi therapeutic, solidifying its market position as a trailblazer in the biopharmaceutical landscape.
DitchCarbon Score
How does Alnylam Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alnylam Pharmaceuticals's score of 66 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alnylam Pharmaceuticals's reported carbon emissions
In 2024, Alnylam Pharmaceuticals reported total carbon emissions of approximately 183,000,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 160,000,000 kg CO2e. Specifically, Scope 1 emissions were about 3,832,000 kg CO2e, and Scope 2 emissions were approximately 8,018,000 kg CO2e (market-based). The company has set ambitious reduction targets, aiming to decrease its Scope 1 and Scope 2 emissions by 30% from 2020 levels by the year 2030. This commitment reflects a proactive approach to climate responsibility, aligning with industry standards for emissions reduction. In 2023, Alnylam's emissions were slightly lower, with total emissions of about 151,000,000 kg CO2e, including approximately 3,546,000 kg CO2e from Scope 1 and 9,918,000 kg CO2e from Scope 2 (market-based). The trend indicates a focus on improving sustainability practices, although the majority of emissions still stem from Scope 3 activities, particularly in purchased goods and services. Overall, Alnylam Pharmaceuticals is actively working towards reducing its carbon footprint while maintaining transparency in its emissions reporting and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 3,054,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,518,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 3,064,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Alnylam Pharmaceuticals's Industry?
How Carbon Intensive is Alnylam Pharmaceuticals's Location?
Alnylam Pharmaceuticals's Scope 3 Categories Breakdown
Alnylam Pharmaceuticals's Scope 3 emissions, which increased by 6% last year and increased significantly since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
Alnylam Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alnylam Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
